The CNS market is one of the largest and fastest growing markets in the biopharmaceutical industry. Yet, despite a growing global need for novel CNS treatments, development of therapies for CNS diseases has lagged behind other areas. In this article, experts from Parexel’s BioPharm Unit identify three strategies that apply multidisciplinary solutions earlier in the development process to reduce failures and accelerate CNS drug development.
We are at the beginning of an era when CNS drug development requires both flexibility and creativity on the part of drug developers. For those involved in CNS drug development, the opportunities are significant.